Ngokwemiphumela yokulandelwa kweminyaka emihlanu kwecala elibalulekile le-PACE elishicilelwe ku-Journal of Hematology, i-panatinib (Ponatinib, Iclusig) igcine ukuhlala isikhathi eside ezigulini eziphathwe kabi ezinesifo esingapheli se-myeloid leukemia (CP-CML) ukusabela.
Ngokwesilinganiso sokulandelwa kwezinyanga ze-56.8, i-60% (n = 159) yeziguli ezihlolekayo ze-267 izuze impendulo enkulu yeselula (MCyR). Ama-54% (n = 144) eziguli abe nempendulo ephelele yeselula. 40% (n = 108) patients achieved a major molecular response (MMR), and 24% (n = 64) achieved a molecular response. During the median follow-up period, at 12 months, 82% of patients achieved MCyR, and at 5 years, an estimated 59% of patients achieved MMR. The most common (≥40%) adverse events (TEAE) were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%) and constipation (41%).
In the entire 270 patient cohort, more than 90% of patients had received at least 2 TKI treatments. Investigators found that the response was related to long-term results. The 5-year progression-free survival (PFS) is expected to be 53%, and the overall survival (OS) is 73%.
Ukukhishwa kwale mininingwane kuyingqophamlando ebalulekile ngoba kukhombisa ukuthi iPonatinib kuseseyindlela yokwelashwa ephumelelayo yeziguli ezifanele ezinokwehluleka kwe-TKI yangaphambilini (kufaka phakathi iziguli ezine-T315I mutation).
